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ABSTRACT  21 
The interferon induced transmembrane protein (IFITM) family of proteins inhibit infection 22 
of several different enveloped viruses in cell culture by virtue of their ability to restrict entry and 23 
fusion from late endosomes. As few studies have evaluated the importance of IFITM3 in vivo in 24 
restricting viral pathogenesis, we investigated its significance as an antiviral gene against West 25 
Nile virus (WNV), an encephalitic flavivirus, in cells and mice. Ifitm3-/- mice were more vulnerable 26 
to lethal WNV infection, and this was associated with greater virus accumulation in peripheral 27 
organs and central nervous system tissues. As no difference in viral burden in the brain or 28 
spinal cord was observed after direct intracranial inoculation, Ifitm3 likely functions as an 29 
antiviral protein in non-neuronal cells. Consistent with this, Ifitm3-/- fibroblasts but not dendritic 30 
cells resulted in higher yields of WNV in multi-step growth analyses. Moreover, trans-31 
complementation experiments showed that Ifitm3 inhibited WNV infection independently of 32 
Ifitm1, Ifitm2, Ifitm5, and Ifitm6. Beyond a direct effect on viral infection in cells, analysis of the 33 
immune response in WNV-infected Ifitm3-/- mice showed decreases in the total number of B 34 
cells, CD4+ T cells, and antigen-specific CD8+ T cells. Finally, bone marrow chimera 35 
experiments demonstrated that Ifitm3 functioned in both radioresistant and radiosensitive cells, 36 
as higher levels of WNV were observed in the brain only when Ifitm3 was absent from both 37 
compartments. Our analyses suggest that Ifitm3 restricts WNV pathogenesis likely through 38 
multiple mechanisms including the direct control of infection in subsets of cells.  39 
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As part of the mammalian host response to viral infections, hundreds of interferon-42 
stimulated genes (ISGs) are induced. The inhibitory activity of individual ISGs varies depending 43 
on the specific cell type and viral pathogen. Among ISGs, the interferon-induced 44 
transmembrane proteins (IFITM) genes have been reported to inhibit multiple families of viruses 45 
in cell culture. However, few reports have evaluated the impact of IFITM genes on viral 46 
pathogenesis in vivo. In this study, we characterized the antiviral activity of Ifitm3 against West 47 
Nile virus (WNV), an encephalitic flavivirus, using mice with a targeted gene deletion of Ifitm3. 48 
Based on extensive virological and immunological analyses, we determined that Ifitm3 protects 49 
mice from WNV-induced mortality by restricting virus accumulation in peripheral organs and 50 
subsequently, in central nervous system tissues. Our data suggest that Ifitm3 restricts WNV 51 
pathogenesis by multiple mechanisms and functions in part, by controlling infection in different 52 
cell types.  53 
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INTRODUCTION  55 
The interferon (IFN) induced transmembrane protein (IFITM) genes consist of a family of 56 
related proteins; Ifitm1, 2, 3, 5, 6, 7, and 10 in mice and IFITM1, 2, 3, 5, and 10 in humans (1, 57 
2). The expression of several IFITM genes, (e.g., IFITM1, 2, and 3) can be induced by type I, II, 58 
or III IFNs (3, 4). Although initial studies described possible roles of IFITM1, IFITM2, and IFITM3 59 
in development, apoptosis, cell proliferation, and cell signaling (5–13), a subsequent report 60 
suggested that ectopic expression of IFITM1 in mouse L cells could restrict infection of vesicular 61 
stomatitis virus (VSV) (14). A decade later, gene silencing and ectopic expression studies 62 
established that IFITM proteins have antiviral activity in cell culture against members of the 63 
Flaviviridae, Orthomyxoviridae, Filoviridae, Rhabdoviridae, Retroviridae, Bunyaviridae, 64 
Reoviridae, Togaviridae, and Paramyxoviridae families (15–28). Nonetheless, some enveloped 65 
and non-enveloped viruses appear resistant to the actions of IFITM proteins including 66 
arenaviruses, papillomaviruses, cytomegaloviruses, and adenoviruses (16, 17, 29).   67 
IFITM proteins are transmembrane proteins. Although their precise membrane topology 68 
remains uncertain (5, 6, 15, 30–36), recent studies suggest that they are type II membrane 69 
proteins (35–37). Moreover, the cellular sublocalization of the IFITM proteins varies among 70 
family members, with IFITM1 expressed primarily at the plasma membrane, and IFITM2 and 71 
IFITM3 colocalizing predominantly with late endosomes (20, 32). Based on the cellular 72 
localization and effects on specific steps in viral lifecycles, IFITM1, IFITM2, and IFITM3 appear 73 
to restrict fusion and uncoating of viruses into the cytoplasm (33, 38, 39), with different IFITM 74 
proteins inhibiting specific viruses in distinct membrane compartments. Despite the intensive 75 
study of the IFITM proteins in cell culture, the precise mechanism of restriction of viral fusion 76 
has remained elusive. It has been suggested that IFITM proteins can increase cholesterol 77 
accumulation in endosomes, alter membrane fluidity, or make fusion events energetically 78 
unfavorable (17, 33, 38, 40). IFITM1, IFITM2, and IFITM3 also can become incorporated into 79 
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 Although IFITM proteins can restrict infection of many viruses in cell culture, their 81 
importance in vivo in the context of a complex IFN response with hundreds of other interferon-82 
stimulated genes (ISGs) remains less well characterized. Two publications have reported that 83 
Ifitm3-/- mice are more susceptible to influenza A virus (IAV) infection (3, 43). These studies 84 
described increased IAV titers in the lung, increased pathology, and decreased CD4+ T cells, 85 
CD8+ T cells, and NK cells in Ifitm3-/- compared to WT mice. One of these studies described a 86 
human polymorphism in IFITM3, (SNP-rs12252-C) that results in an altered splice acceptor site, 87 
which truncates the N-terminal 21 amino acids of IFITM3. This truncated IFITM3 protein showed 88 
altered cellular localization and reduced antiviral activity against IAV (32, 43, 44). A second 89 
study demonstrated that CD8+ resident memory T cells expressed high levels of Ifitm3 in the 90 
lung following IAV infection, and that Ifitm3 expression was important for memory T cell survival 91 
against virus rechallenge (45). Ifitm3 also reportedly has an antiviral role against respiratory 92 
syncytial virus in vivo, as Ifitm3-/-  mice sustained higher viral burden in the lungs (46). To date, 93 
no studies have described an antiviral role of Ifitm3 in vivo apart from viruses that preferentially 94 
infect the lung.  95 
West Nile virus (WNV) is a neurotropic, mosquito-transmitted, positive-stranded, 96 
enveloped RNA virus in the Flaviviridae family, which includes several viruses of global concern 97 
such as Dengue (DENV), Zika (ZIKV), yellow fever (YFV), and Japanese encephalitis (JEV) 98 
viruses. Whereas most infections with WNV in humans are asymptomatic, ~30% develop a 99 
febrile illness, which can progress to severe neurological disease including meningitis, flaccid 100 
paralysis, encephalitis, and death (47, 48). Several studies have established that IFN signaling 101 
and induction of downstream antiviral effector proteins (e.g., IFIT2, viperin, PKR, RNAse L, and 102 
Ifi27l2a) restrict the tropism and dissemination of WNV (49–52). Here, we examined the role of 103 
Ifitm3 in vivo in restricting infection of WNV using Ifitm3-/- mice. Extensive virological and 104 
immunological analysis revealed that Ifitm3-/- mice were more vulnerable to WNV infection with 105 
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contribution of Ifitm3 to controlling WNV in peripheral organs prior to dissemination to the brain 107 
and infection and injury of target neuron populations. 108 
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MATERIALS AND METHODS 110 
Ethics statement. This study was carried out in strict accordance with the 111 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 112 
Institutes of Health. The protocols were approved by the Institutional Animal Care and Use 113 
Committee at the Washington University School of Medicine (Assurance Number: A3381-01). 114 
Dissections and footpad injections were performed under anesthesia that was induced and 115 
maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize 116 
suffering. 117 
Virus propagation. The WNV strain New York 1999 (53, 54) was passaged in Vero 118 
cells to generate a mammalian cell derived stock. The WNV strain from Madagascar (DakAnMg 119 
798, WNV-MAD) was isolated in 1978 and also passaged in Vero cells (55). Titration of viral 120 
stocks was performed using a focus-forming assay as described previously (56).  121 
Mouse experiments and tissue preparation Wild-type (WT) C57BL/6 (000664) or 122 
B6.SJL (002014) mice were purchased from Jackson Laboratory. Ifitm3-/- mice were generated 123 
previously (57), backcrossed using speed congenics onto a C57BL/6J background, and bred in 124 
a pathogen free animal facility at the Washington University School of Medicine. Eight to ten 125 
week-old age and sex-matched mice were used. Mice were infected via a subcutaneous (102 126 
FFU in 50 μl) or intracranial (101 FFU in 10 μl) route with virus diluted in PBS. For survival 127 
studies, infected mice were monitored for 21 days. For viral burden studies, at specified time 128 
points after infection, serum was collected and animals were perfused with 20 ml of PBS. 129 
Subsequently, the spleen, kidney, draining lymph node, brain, and spinal cord were harvested, 130 
weighed, homogenized by bead dissociation using a MagNA Lyzer (Roche). Virus was titered 131 
by plaque assay on Vero cells (58, 59) or levels of viral RNA were measured by qRT-PCR as 132 
described previously (49, 60).   133 
Measurement of WNV-specific antibodies. WNV-specific IgM and IgG titers were 134 
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reduction neutralization assay were performed on Vero cells after mixing serial dilutions of 136 
serum with a fixed amount (102 FFU) of WNV (56). 137 
Analysis of cellular immune responses. Splenocytes were harvested from WT or 138 
Ifitm3-/- mice on day 7 or 8 after WNV infection. Lymphocyte populations were stained using 139 
anti-CD3-V500 (560711; BD Bioscience), anti-CD8α- or anti- CD8β-Percp Cy5.5 (100734; 140 
Biolegend), anti-CD19-AlexaFluor700 (115528; Biolegend), anti-CD4-BV421 (100437; 141 
Biolegend), anti-granzyme B (GRB04; Invitrogen), and tetramers specific for a Db-restricted 142 
immunodominant peptide in NS4B (62). Brains were harvested from WT or Ifitm3-/- mice on day 143 
8 after WNV infection. CNS leukocytes were isolated by Percoll gradient centrifugation as 144 
described previously (62, 63) and  stained with the antibodies and tetramer described above in 145 
addition to anti-CD11b-PE-Cy7 (101216; Biolegend) and anti-CD45-BV605 (103139; 146 
Biolegend). Cells were analyzed on a BD LSRII flow cytometer and data were processed using 147 
FlowJo software. 148 
To examine intracellular cytokine production by CD4+ and CD8+ T cells, anti-CD3 or 149 
antigen-specific peptide restimulation was performed (62). In brief, splenocytes were isolated 150 
and stimulated with anti-CD3 (100207; Biolegend), the immunodominant NS4B peptide, or no 151 
stimulation. Cells were incubated for 6 h at 37oC in the presence of brefeldin A and then fixed 152 
and permeablized using the FoxP3/Transcription Factor Staining Buffer set (00-5523-00; 153 
eBioscience). Subsequently, cells were stained with anti-CD4-BV421 (100437; Biolegend), anti-154 
CD8β-PerCP-Cy5.5 (126609; Biolegend), anti-CD19-AlexaFluro700 (115528; Biolegend), anti-155 
IFN-γ-APC (51-73-1182; eBioscience), and anti-TNF-α-PE (506306l Biolegend) antibodies and 156 
analyzed. 157 
Primary cell isolation and infection. Primary macrophages (Mφ), dendritic cells (DCs), 158 
and mouse embryonic fibroblasts (MEFs) were generated from WT and Ifitm3-/- mice as 159 
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of infection (MOI) of 5 and 0.01, respectively. In some experiments, cells were pretreated with 161 
IFN-β (12400-1; PBL Assay Science) for 16 h before infection. Viral supernatants were 162 
harvested and titered using a focus-forming assay. 163 
 Transformation of MEFs. MEFs were transfected with the plasmid SV2, which encodes 164 
for the large T antigen of SV40 polyoma virus (65). Cells were passaged ~10 times and used for 165 
subsequent experiments. 166 
 Trans-complementation of MEFs. (a) Production of pFCIV-containing lentivirus.  167 
293T cells were seeded at 5 x 106 cells per well in a 6 well plate. One day later, cells were 168 
transfected with 0.4 μg of pMD.2, 0.8 μg of pSPAX2, and 0.8 μg of pFCIV-c-Myc-Ifitm3 or 169 
pFCIV-c-Myc-Firefly luciferase using FuGENE (Roche) according to the manufacturer’s 170 
instructions (66, 67). Two to three days after transfection, lentivirus was collected from the 171 
supernatant of cells, centifruged at 1,000 x g for 10 min at 4°C to remove cellular debris, and 172 
then stored at -80°C. (b) Generation of MEF transfectants. Transformed MEFs were seeded 173 
at 0.5 x 104 cells per well in a 96 well plate. Six hours after plating, 100 μl of lentivirus + 1 μg 174 
polybrene (sc-134220; Santa Cruz Biotech) were added to each well and cells were 175 
spinoculated at 1,000 x g, for 30 min at 24°C. Six hours later, lentivirus was removed and 176 
replaced with DMEM containing 10% FBS. Cells were passaged and expanded into a T-75 177 
tissue culture flask. Transduced cells were sorted for GFP expression (pFCIV encodes for GFP 178 
under a IRES promoter) on a BD FACsAria II flow cytometer. Cells were passaged five times to 179 
confirm stable expression by GFP expression and c-Myc tagged protein expression using flow 180 
cytometery and then used for subsequent experiments. 181 
 Western blotting of Ifitm3 expression.  WT or Ifitm3-/- MEFs, or Ifitm3-/-  MEFs trans-182 
complemented with c-Myc-Ifitm3 were seeded at 5 x 104 cells per well in a 24 well plate. Cells 183 
were stimulated with or without 10 U/mL of IFN-β for 16 h at 37oC. Cells were washed with PBS 184 
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debris was removed from the sample by centrifugation at 10,000 x g for 10 min at 4oC. The 186 
clarified supernatant was resuspended in 4x LDS sample buffer (NuPAGE NP0008), boiled (5 187 
min at 90oC), and then electrophoresed on a 12% Bis-TRIS gel (NuPAGE NP0343BOX) at 200 188 
V for 40 min in MES buffer (NuPAGE NP0002). Protein was transferred to a PVDF membrane 189 
(Invitrogen IB24002) using an Iblot2 (Life Technologies IB21001) with a standard 7-minute 190 
transfer. A 1:1,000 dilution of mouse anti-β-actin (Protein Tech 11714-1-AP) and rabbit anti-191 
Ifitm3 (Cell Signaling 3700) was prepared in TBS-T + 4% milk and used to stain the membrane 192 
overnight at room temperature. Subsequently, after washing, a 1:10,000 dilution of donkey anti-193 
mouse IRDye 800 (LI-COR 925-32212) or anti-rabbit IRdye 680 (LI-COR 926-68073) was 194 
prepared in TBS-T + 4% milk and used to stain the membrane for 2 h at room temperature. An 195 
Odyssey machine (LI-COR Biosciences) was used to visualize the bands on the membrane.  196 
Infection of MEFs. WT, gene deletion, and trans-complemented MEFs were seeded at 197 
2 x 104 cells per 96 well plate. Sixteen hours later, cells were infected with WNV at a MOI of 5. 198 
Twenty-four hours later, cells were harvested and fixed and permeabilized using 199 
Foxp3/Transcription Factor Staining Buffer set. Subsequently, cells were incubated with rabbit 200 
anti-c-Myc (71D10; Cell Signaling) antibody or humanized E16 (68), a WNV E protein specific 201 
monoclonal antibody. After washing cells, AlexaFluro647-conjugated anti-rabbit-IgG (A-21245 202 
Invitrogen) and AlexaFluor 568-conjugated anti-human IgG (A-21090 Invitrogen) secondary 203 
antibodies were added. Cells were analyzed on a BD LSRII flow cytometer array using FlowJo 204 
software. 205 
 Bone marrow chimera. 107 donor bone marrow cells from CD45.1 (B6.SJL) and 206 
CD45.2 (Ifitm3-/-) mice were transferred adoptively by intravenous injection into 8 week-old 207 
recipient B6.SJL and Ifitm3-/- mice that had been irradiated with 900 cGγ. Mice were infected 8 208 
weeks later with WNV. Tissues were harvested seven days after infection for viral burden and 209 
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 Statistical Analysis. Data was analyzed using Prism Software (GraphPad4, San Diego, 211 
CA).  Kaplan-Meier survival curves were analyzed by the log rank test. A one-way or two-way 212 
ANOVA was used to determine statistically significant differences for in vitro viral growth 213 
experiments. The Mann-Whitney test was used to analyze differences in viral burden, cell 214 
numbers, and antibody titers.  A one-way ANOVA with a multiple comparison correction was 215 
used to analyze difference in viral burden, cell numbers, and antibody titers for bone marrow 216 
chimera experiments.   217 
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 Ifitm3 restricts WNV infection and pathogenesis in mice. IFITM3 is an ISG that has 220 
been reported to restrict infection of several flaviviruses in cell culture, including WNV and 221 
DENV (15, 19, 21–23, 69–71). To determine the role of Ifitm3 in restricting pathogenesis of a 222 
flavivirus in vivo, we inoculated 8 to 9 week-old WT and congenic Ifitm3-/- C57BL/6 mice via a 223 
subcutaneous route with 102 FFU of a pathogenic strain of WNV (New York 1999). Ifitm3-/- mice 224 
were more vulnerable to WNV infection than WT mice, as a greater percentage (90% versus 225 
40% lethality, P < 0.001) succumbed to disease (Fig 1A). The mean time to death of Ifitm3-/- 226 
compared to WT mice was shorter (10.6 versus 11.8 days, P < 0.05), which is consistent with 227 
an accelerated disease course. One to two days before death, WT and Ifitm3-/- mice that 228 
ultimately would die similarly exhibited fur ruffling, hunched posture, and diminished movement. 229 
Within one day of death some of these animals developed clinical evidence of hind limb 230 
paralysis.  231 
 Ifitm3 limits WNV infection in different tissues. To begin to determine how an 232 
absence of Ifitm3 results in enhanced WNV pathogenesis, we measured viral burden in the 233 
serum, spleen, kidney, draining lymph nodes, brain, and spinal cord at days 2, 4, 6, and 8 post 234 
infection after subcutaneous infection. 235 
 Relatively small, yet statistically significant differences in viral burden were observed in 236 
some peripheral organs. For example, viremia was equivalent at day 2 after WNV infection but 237 
higher at days 4 and 6 in Ifitm3-/- compared to WT mice (Fig 1B, P < 0.01). Increased viral titers 238 
also were detected in the draining lymph node (DLN) days 6 and 8 after infection (Fig 1C, P < 239 
0.05). However, an increase in WNV infection was not detected in the spleen at any of the time 240 
points (Fig 1D, P > 0.05). Viral yield remained near the limit of detection in the kidney of Ifitm3-/- 241 
mice (data not shown); in WT mice, this organ is normally resistant to WNV infection, but 242 
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 We next assessed the impact of Ifitm3 on viral replication in the brain and spinal cord, 244 
which are targets of WNV infection in mice and humans (74). Higher viral titers were observed 245 
in the brains of Ifitm3-/- compared to WT mice at day 6 after infection (Fig 1E, P < 0.05) and in 246 
the spinal cord of Ifitm3-/- mice on days 6 and 8 after infection (Fig 1F, P < 0.05). Overall, an 247 
absence of Ifitm3 resulted in enhanced viral replication in the CNS.   248 
 Ifitm3 does not directly restrict WNV in infection in the CNS. The higher WNV titers 249 
in the brain and spinal cord of Ifitm3-/- mice could reflect enhanced replication in peripheral 250 
organs and viremia, which results in increased seeding of CNS tissues. Alternatively, it could be 251 
due to intrinsic antiviral effects of Ifitm3 in cells of the CNS. Although Ifitm3 is expressed in 252 
neurons at baseline and after type I IFN induction (74), it remains unknown whether Ifitm3 has 253 
an antiviral role in neurons in vivo. To evaluate this question, WT and Ifitm3-/- mice were infected 254 
with 101 FFU of WNV directly into the cerebral cortex via an intracranial route, and viral burden 255 
in the cerebral cortex, white matter, brain stem, cerebellum, and spinal cord was measured on 256 
days 3 and 5 after infection. Notably, no difference in viral burden was detected in CNS tissues 257 
on day 3 or day 5 after infection (Fig 2A-F, P > 0.05). Because the virulent strain of New York 258 
strain of WNV can antagonize IFN responses (75, 76), we repeated intracranial infection studies 259 
with an attenuated strain (Madagascar 1978 (WNV-MAD)) that is more sensitive to type I IFN 260 
(77). Again, no significant difference in viral burden was observed in CNS tissues of WNV-MAD-261 
infected WT and Ifitm3-/- mice (Fig 2G-L, P > 0.05). These data suggest that the increased CNS 262 
titers in Ifitm3-/- mice after subcutaneous WNV infection were not due to direct antiviral effects in 263 
neuronal cells.  264 
 T cell responses in Ifitm3-/- mice. A previous study reported reduced CD8+ T cell 265 
numbers in Ifitm3-/- mice during acute IAV infection (43). Another study demonstrated that lung 266 
resident memory CD8+ T cells with reduced Ifitm3 expression were vulnerable to IAV infection 267 




ber 14, 2016 by W







can facilitate enhanced replication of WNV in the CNS (62, 78, 79), we investigated whether an 269 
absence of Ifitm3 influenced the development of an adaptive immune response during infection.   270 
 At day 7 after WNV infection, splenocytes were harvested and the percentage and 271 
number of bulk CD4+ and CD8+ T cells and NS4B tetramer-specific CD8+ T cells were 272 
determined. Although differences in T cell numbers were not detected at baseline in naïve mice, 273 
the number of CD4+ T cells, CD8+ T cells, and NS4B tetramer-specific CD8 T cells was 274 
decreased in Ifitm3-/- mice after WNV infection (Fig 3A-F, and M). To assess whether antigen-275 
specific CD8+ T cells showed qualitative defects in the absence of Ifitm3, splenocytes were from 276 
WNV-infected mice were stimulated ex vivo with an immunodominant WNV NS4B peptide and 277 
tested for cytokine production. However, equivalent percentages, numbers, and geometric 278 
mean fluorescence intensity of IFN-γ and TNF-α producing CD8+ T cells were detected in WT 279 
and Ifitm3-/- mice (Fig 3G-L and N, P > 0.05). 280 
 A small decrease in the number of antigen-specific CD8+ T cells in the periphery of 281 
Ifitm3-/- mice could impact the accumulation of these cells in the CNS and viral clearance. As 282 
such, we compared the number of immune cells in the brains of WT and Ifitm3-/- mice at day 8 283 
after infection by flow cytometry. We did not observe differences in the numbers of activated 284 
microglia (CD11bhigh CD45low) or macrophages (CD11bhigh CD45high) (Fig 4A-D and 4S, P > 285 
0.05) in brains of WNV-infected WT and Ifitm3-/- mice. Moreover, similar percentages and 286 
numbers of NS4B tetramer+ and granzyme B+ CD8+ T cells were detected (Fig 4E-L, P > 0.05). 287 
Also, after ex vivo restimulation with the NS4B peptide, equivalent percentages and numbers of 288 
IFN-γ and TNF-α secreting CD8+ T cells were measured from the brains of WT and Ifitm3-/- mice 289 
(Fig 4M-R, and 4T, P > 0.05). Thus, while a small decrease in CD8+ T cell response in the 290 
periphery of WNV-infected Ifitm3-/- mice was observed, it did not appear to impact clearance of 291 
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 B cell responses in Ifitm3-/- mice.  Antiviral antibody responses restrict dissemination of 293 
WNV in vivo into the CNS (59, 80). As such, we determined whether Ifitm3 expression 294 
modulated antiviral antibody responses. Whereas baseline numbers of CD19+ B cells were 295 
similar in naïve mice, we observed a decrease in their number in the spleen in Ifitm3-/- mice at 296 
day 7 after infection (Fig 5A and B). To assess the effect on antiviral antibody responses, we 297 
analyzed serum from WT and Ifitm3-/- mice on day 8 after infection for binding to WNV E protein. 298 
Although anti-WNV IgM titers were equivalent between WT and Ifitm3-/- mice (Fig 5C, P > 0.05) 299 
the anti-WNV IgG response was greater in Ifitm3-/- mice at day 8 after infection (Fig 5D, P < 300 
0.05), possibly due to the higher levels of virus in peripheral organs. To evaluate the functional 301 
quality of anti-WNV antibody from WT and Ifitm3-/- mice, we assessed neutralizing activity. No 302 
difference in inhibitory activity was detected in serum from WT and Ifitm3-/- mice at day 8 post 303 
infection (Fig 5E; P > 0.05). These data suggest that while there might be small effects of Ifiitm3 304 
on B cell responses, these do not translate into depressed antiviral antibody responses, and 305 
thus likely do not contribute to the increased WNV infection observed in different organs in 306 
Ifitm3-/- mice.  307 
 Ifitm3 controls WNV infection in some primary cells. To gain further insight in which 308 
cells require Ifitm3 for optimal restriction of WNV infection, we compared multi-step growth 309 
kinetics and effects of IFN-β treatment in different primary cells derived from WT and Ifitm3-/- 310 
mice including Mφ, DCs, and fibroblasts (MEFs). Although we did not observe statistically 311 
increased viral yields in unstimulated Ifitm3-/- Mφ (Fig 6A), pretreatment of ifitm3-/- Mφ with low 312 
doses of IFN-β to stimulate ISG production did produce marginally higher levels virus (Fig 6B-313 
C). In comparison, unstimulated or IFN-β-treated Ifitm3-/- DC did not support statistically 314 
increased WNV infection (Fig 6D-F). However, multi-step growth analysis demonstrated 315 
increased WNV yield in the supernatants of Ifitm3-/- compared to WT MEFs (Fig 6G, P < 0.05) 316 
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Single-step growth kinetic analysis failed to demonstrate increased WNV yield of unstimulated 318 
ifitm3-/- MEFs (Fig 6I, P>0.05) although pretreatment with IFN-β did show an effect (Fig 6J, P 319 
<0.05). Thus, Ifitm3 restricts WNV infection in some cell types although its expression must be 320 
induced to observe this phenotype. 321 
 To confirm that the increased permissiveness of Ifitm3-/- MEF for WNV was due to the 322 
loss of Ifitm3, we trans-complemented cells with a c-Myc tagged form of Ifitm3 (c-Myc-Ifitm3) 323 
and compared this to a control c-Myc tagged form of Firefly luciferase (c-Myc-FLUC) (Fig 6K-324 
M).  Lentiviral-mediated expression of c-Myc tagged Ifitm3 first was validated by Western 325 
blotting (Fig 6K). Untransduced and c-Myc-FLUC transduced Ifitm3-/- and Ifitm12356-/- (locus 326 
deletion) MEFs sustained higher WNV infection as judged by viral antigen staining and flow 327 
cytometry when compared to the comparable Ifitm3-sufficient WT MEFs (3 to 4-fold, P < 0.05). 328 
However, ectopic expression of c-Myc-Ifitm3 reduced WNV infection in WT, Ifitm3-/- (13-fold, P < 329 
0.01) and Ifitm12356-/- (21-fold, P < 0.001) compared to expression of FLUC in these cells. 330 
These data suggest that the relative susceptibility Ifitm3-/- and Ifitm12356-/- MEFs to WNV 331 
infection is due largely to the loss of expression of Ifitm3, and that Ifitm3 can function as an 332 
antiviral molecule in the absence of expression of Ifitm1, Ifitm2, Ifitm5, and Ifitm6. 333 
 Ifitm3 expression on radioresistant and radiosensitive cells restricts WNV 334 
infection. Our data in primary cells suggested that Ifitm3 might have antiviral effects in cells of 335 
different lineages. To assess the relative importance of Ifitm3 in different cellular compartments 336 
in vivo, we generated reciprocal bone marrow chimera using congenic CD45.1+ (WT) and 337 
CD45.2+ (Ifitm3-/-) donor and recipient mice, and viral burden was measured at 7 days after 338 
infection (Fig 7A-B). Due to the process of irradiation and reconstitution, the chimeric mice 339 
necessarily were infected at an older age, 16 weeks, compared to the other studies (see Fig 1). 340 
Bone marrow chimeras with Ifitm3-/- or WT radio-resistant non-hematopoietic cells (WTIfitm3–/– 341 
or Ifitm3–/–WT) had equivalent levels of virus in serum, draining lymph node and spinal cord 342 
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(Ifitm3–/–Ifitm3-/-) sustained higher titers in the brain (Fig 7E, P < 0.05), as seen with the direct 344 
gene deletions (see Fig 1). Analysis of the adaptive immune response revealed minor 345 
differences in the chimeric mice. The percentage of CD19+ B cells was higher in Ifitm3–/–Ifitm3-346 
/- mice (Fig 7G), but no difference in the absolute number of CD19+ B cells was observed (Fig 347 
7H). CD4+ T cell numbers and percentages in the spleen also were similar (Fig 7I-J). The 348 
percentage of CD8+ T cells was reduced in Ifitm3–/–WT and Ifitm3–/–Ifitm3-/- mice (Fig 7K), 349 
but this did not affect the total number of CD8+ T cells or the number or percentage of NS4B 350 
tetramer+ CD8+ T cells (Fig 7L-N). Thus, Ifitm3 expression in both radioresistant and 351 
radiosensitive cell compartments contributes to the control of WNV infection, and only when 352 
there is a lack of Ifitm3 in both compartments is the phenotype of enhanced infection in the CNS 353 
revealed. 354 
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 Based primarily on studies in cell culture, the ISG IFITM3 has been suggested to have 357 
antiviral activity against a variety of viral pathogens, including flaviviruses (16–27). A 358 
demonstrable antiviral role for IFITM3/Ifitm3 in vivo has been established previously only for IAV 359 
and RSV (3, 43, 45, 46). We explored the function of Ifitm3 in restricting WNV pathogenesis in 360 
mice. Survival analysis revealed that Ifitm3-/- mice were more vulnerable to lethal WNV infection. 361 
This enhanced susceptibility was associated with increased viral infection in both peripheral and 362 
CNS tissues. Our culture studies with primary cells confirm an antiviral role of IFITM3 against 363 
WNV and extend these findings to a physiologically relevant in vivo system. 364 
 Several studies have examined the interaction between IFITM proteins and Flaviviridae 365 
members in cell culture (15, 19, 23, 69–71). DENV, WNV, YFV, and recently ZIKV were shown 366 
to be susceptible to IFITM-mediated antiviral restriction with IFITM3 being the most potent 367 
antiviral IFITM protein in cell culture (15, 71, 81). Mechanism of action studies demonstrated 368 
that IFITM3 had no significant effect of WNV RNA replication (19). Rather, flavivirus infection 369 
likely is inhibited by IFITM3 at the fusion step in the late endosome, analogous to its antiviral 370 
actions on IAV (33, 38, 39). Other work has shown that IFITM1, IFITM2, and IFITM3 all can 371 
restrict DENV infection including under conditions of antibody dependent enhancement (23). 372 
Our trans-complementation experiments in Ifitm12356-/- MEFs extend these findings by showing 373 
that Ifitm3 can inhibit infection of WNV independently of expression of Ifitm1, Ifitm2, Ifitm5, and 374 
Ifitm6. This data argues strongly against an essential role for heteromeric complexes of different 375 
IFITM proteins in the antiviral activity of IFITM3 (70, 82).   376 
 Few studies have examined the function of IFITM3 in vivo. Increased lethality of Ifitm3-/- 377 
mice was observed after challenge with IAV (43), and this was associated with increased viral 378 
titers in the lung, increased lung pathology, and lymphopenia compared to WT mice. An 379 
additional study observed that Ifitm3-/- and Ifitm12356-/- mice were equally susceptible to IAV 380 
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WNV infection in Ifitm12356-/- mice, as virtually all of these animals were stillborn when crossed 382 
onto a pure C57BL/6J background (M. J. Gorman and M. S. Diamond, unpublished 383 
observations), which is consistent with the original description of several IFITM proteins having 384 
a role in germ cell development (57, 83–85). Ifitm3-/- also were susceptible to another respiratory 385 
virus, RSV, with increased viral titers in the lung after infection (46). Ifitm3, however, does not 386 
restrict all pathogens, as Ifitm3-/- mice were not more susceptible to Salmonella typhimurium, 387 
Citrobacter rodentium, Mycobacterium tuberculosis or Plasmodium berghei (46). 388 
Prior studies have demonstrated Ifitm3 expression throughout the lung, spleen, lymph 389 
node, liver, and intestine suggesting that this protein may have broad antiviral functions in many 390 
tissues (3, 46). One of these functions may be the protection of immune cells such as CD8+ 391 
resident memory T cells or dendritic cells, as increased IAV infection and reduced survival were 392 
observed in Ifitm3-deficient T cells and dendritic cells (45, 86). Our studies demonstrate that 393 
neurotropic viruses also are restricted by Ifitm3 in vivo, although this phenotype appeared 394 
largely independent of a cell-intrinsic antiviral effect in the CNS. Our data is more consistent 395 
with a dominant antiviral effect of Ifitm3 in cells of peripheral organs, which then limits viremia 396 
and seeding of neurons in the brain and spinal cord. Our bone marrow chimera experiments 397 
suggest that Ifitm3 expression on both radioresistant and radiosensitive cells contributes to the 398 
control of WNV infection and pathogenesis in vivo. Definitive identification of the cells types in 399 
vivo that require Ifitm3 for antiviral protection await the generation of conditional gene deletion 400 
mice. 401 
Similar to previously reported results, we discovered several adaptive immune 402 
deficiencies during viral infection. IAV challenge models had demonstrated that Ifitm3-/- mice 403 
had reduced CD4+ T cells and CD8+ T cell response in the lung during infection (43, 45). Our 404 
data demonstrated a similar phenotype, with CD4+ T cells, CD8+ T cells, and CD19+ B cells 405 
being reduced in the spleen during WNV infection. Despite this, antibody responses and CNS 406 
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Our bone marrow chimera experiments demonstrated that while the radiosensitive cells of the 408 
adaptive immune response may be important, they are not the dominant cell type leading to 409 
increased CNS viral burden.   410 
IFITM3 is one of several ISGs that restrict WNV in vivo in mice. Antiviral functions 411 
against WNV have been documented for protein kinase R (PKR), RNAse L, Ifit2, Ifit27l2a, and 412 
viperin (49–52). Ifit2, Ifi27l2a, and viperin had antiviral functions that were limited largely to 413 
neurons in the CNS. Our data suggests that the dominant antiviral function of Ifitm3 likely occurs 414 
before WNV reaches the brain. Individual ISGs appear to have compartmentalized functions, 415 
and restrict WNV infection in a tissue-specific manner. The basis of this remains uncertain but 416 
could be determined by relative expression or interaction with partner proteins that are 417 
differentially expressed. Moreover, despite a highly intricate IFN-dependent signaling cascade in 418 
which hundreds of ISGs are induced in a single cell, deletion of single effector genes still can 419 
impact control of viral infection and disease outcome. 420 
In summary, our study has demonstrated that Ifitm3 has an important antiviral function in 421 
vivo against WNV. As IFITM3 is one of several IFITM family members, which differ in their 422 
cellular localization, expression, and range of viral restriction, additional work is needed to 423 
determine whether other IFITM proteins have analogous antiviral functions in vivo. 424 
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FIGURE LEGENDS 693 
Figure 1. Survival and viral burden analysis of WT and Ifitm3-/- mice. A. Eight to ten 694 
week-old age-matched WT (n = 28) and Ifitm3-/- (n = 23) C57BL/6 mice were infected via 695 
subcutaneous route with 102 FFU of WNV (New York 1999) and monitored for mortality for 21 696 
days. Survival differences were analyzed by the log rank test (P < 0.005). B to F. WNV tissue 697 
burden in WT and Ifitm3-/- mice after subcutaneous infection. WNV levels in serum (B), draining 698 
lymph node (C), spleen (D), brain (E), and spinal cord (F) were measured by qRT-PCR (B-C) or 699 
plaque assay (D-F). Solid lines represent the median viral titers, and dotted lines denote the 700 
limit of detection of the assay. 2-3 mice were used per independent experiment and 5-7 701 
independent experiments were performed. Asterisks indicate statistically significant differences 702 
by the Mann-Whitney test (* P < 0.05, ** P < 0.01, *** P < 0.001).  703 
 Figure 2. No difference in CNS viral burden via intracranial route of inoculation. 704 
Eight to ten week-old age-matched WT and Ifitm3-/- C57BL/6 mice were inoculated via an 705 
intracranial route with 101 FFU of (A-F) WNV (New York 1999) or (G-L) WNV-MAD 706 
(Madagascar 1978). Tissues were harvested at day 3 or day 5 after infection. WNV levels in 707 
olfactory bulb (A, G), brain stem (B, H), cerebellum (C, I), cerebral cortex white matter (D, J), 708 
cerebral cortex gray matter (E, K), and spinal cord (F, L) were measured by plaque assay. Solid 709 
lines represent the median viral titers, and dotted lines denote the limit of detection of the assay. 710 
2-3 mice were used per independent experiment, and 3-4 independent experiments were 711 
performed. None of the comparisons were statistically different as determined by the Mann-712 
Whitney test (Panels A-L, P > 0.05). 713 
 Figure 3. Ifitm3-/- mice have blunted T cell responses in the spleen after WNV 714 
infection. Immune responses were examined in the spleen after subcutaneous inoculation of 715 
102 FFU of WNV (New York 1999). Spleens were harvested on day 7 (A-H) or 8 (I-N) after 716 
infection. The percentage of live cells and total cell population of (A-B) CD3+ CD4+ T cells, (C-D) 717 
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CD8+ T cells and total numbers of CD3+ CD8+ T cells that expressed IFN-γ (G-H), TNF-α (I-J), 719 
or TNF-α and IFN-γ (K-L) after ex vivo stimulation with NS4B peptide are indicated. 720 
Representative flow cytometry plots of NS4B-specific CD3+ CD8+ T cells (M) and CD3+ CD8+ 721 
that express TNF-α and IFN-γ after peptide restimulation (N) are shown. 4-5 mice were used 722 
per independent experiment, and 4 independent experiments were performed. Statistical 723 
significance was determined by the Mann-Whitney test (* P < 0.05, ** P < 0.01). 724 
 Figure 4. Ifitm3-/- mice have normal levels of immune cell populations in the brain 725 
after WNV infection. CNS immune responses were examined after subcutaneous inoculation 726 
of of 102 FFU of WNV (New York 1999). Brains were harvested day 8 post infection. The 727 
percentage and total number of (A-B) CD11b+ CD45lo microglia, (C-D) CD11b+ CD45hi 728 
macrophages, (E-F) CD4+ T cells, (G-H) CD8+ T cells, (I-J) CD8+ granzyme B+ T cells, and (K-729 
L) NS4B-specific CD8+ T cells are shown. The percentage and total number of CD8+ T cells that 730 
expressed (M-N) IFN-γ, (O-P) TNF-α, or (Q-R) both IFN-γ and TNF-α after NS4B peptide 731 
restimulation are shown.  3 mice were used per independent experiment and 3 independent 732 
experiments were performed. None of the comparisons were statistically different as determined 733 
by the Mann-Whitney test (P > 0.05). 734 
 Figure 5. Ifitm3-/- mice have reduced B cell numbers but not reduced antiviral 735 
antibody titers. A-B. Spleens were harvested at day 7 after after subcutaneous inoculation of 736 
WNV (New York 1999). (A) The percentage and (B) total cell numbers of B cells were 737 
determined by flow cytometry.  C-E. Serum was harvested at day 8 after infection. IgM and IgG 738 
antibody titers (C, D) were determined using an ELISA against purified WNV E protein. Serum 739 
neutralization activity (E) was evaluated using an focus reduction neutralization test, and data 740 
was fitted by regression analysis to obtain EC50 values. 2-5 mice were used per independent 741 
experiment, and 4 independent experiments were performed. Statistical significance was 742 
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 Figure 6. WNV infection in Mφ, DC, and MEFs. Bone marrow derived Mφ (A-C) and 744 
DCs (D-F) were infected at a MOI of 0.01 with WNV (New York 1999) and MEFs (G-J) were 745 
infected at an MOI of 5 or 0.01 with WNV (New York 1999). In some experiments, cells were 746 
pretreated for 16 h with 0 0.1, 1, or 10 U/mL of IFN-β. Viral titers were determined by focus-747 
forming assays and reflects at least three independent experiments. K-M. Transformed WT, 748 
Ifitm12356-/-, or Ifitm3-/- MEFs were transduced with lentiviruses expressing a c-Myc tagged 749 
Ifitm3 or Firefly luciferase (FLUC).  Lentiviral-mediated expression of Ifitm3 was validated by 750 
Western blotting and compared to endogenous Ifitm3 expression levels in WT MEFs pretreated 751 
for 16 h with 10 U/mL of IFN-β (K). Transduced MEFs were infected with WNV (New York 1999) 752 
at an MOI of 0.01 for 24 h. Cells were harvested and flow cytometry was used to detect 753 
expression of c-Myc tagged proteins and WNV-infected cells. Representative flow cytometry 754 
plots (L) and pooled data (M) are shown from at least 3 independent experiments performed in 755 
duplicate. Statistical significance in this Figure was determined by a one-way (M) or two-way (A-756 
J) ANOVA (* P < 0.05, ** P < 0.01, *** P < 0.001).   757 
 Figure 7.  Ifitm3 has functions in both the hematopoietic and nonhematopoietic 758 
cell compartments to restrict WNV infection. (A) CD45.1+ B6.SJL and CD45.2+ Ifitm3-/- mice 759 
were sublethally irradiated and reconstituted with either CD45.1+ B6.SJL or CD45.2+ Ifitm3-/- 760 
bone marrow (107 cells). Representative flow cytometry plots are shown of CD45.1 versus 761 
CD45.2 for CD19+ B cells and CD3+ T cells after reconstitution (B). Sixteen week-old chimeric 762 
mice were inoculated via subcutaneous route with 102 FFU of WNV (New York 1999) and 763 
tissues were harvested at day 7 after infection. WNV levels in serum (C), draining lymph node 764 
(D), brain (E), and spinal cord (F) were measured by qRT-PCR (C-D) or by infectious plaque 765 
assay (E-F). Solid lines represent the median viral titers, and dotted lines denote the limit of 766 
detection of the assay. Percentage and total cell numbers in the spleen of (G-H) CD19+ B cells, 767 
(I-J) CD3+ CD4+ T cells, (K-L) CD3+ CD8+ T cells, (M-N) NS4B-specific CD3+ CD8+ T cells. 2-4 768 
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performed. Asterisks indicate values that are statistically significant by a non-parametric (C-F) or 770 
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